AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Zevin Asset Management LLC

Zevin Asset Management LLC decreased its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 3.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 148,186 shares of the company's stock after selling 4,689 shares during the period. AstraZeneca comprises 1.7% of Zevin Asset Management LLC's portfolio, making the stock its 27th largest holding. Zevin Asset Management LLC's holdings in AstraZeneca were worth $10,892,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Banque Transatlantique SA purchased a new position in shares of AstraZeneca during the 4th quarter valued at $26,000. Confluence Investment Management LLC bought a new stake in AstraZeneca during the first quarter valued at about $27,000. Larson Financial Group LLC lifted its position in shares of AstraZeneca by 297.9% in the first quarter. Larson Financial Group LLC now owns 386 shares of the company's stock valued at $28,000 after acquiring an additional 289 shares in the last quarter. Mascagni Wealth Management Inc. bought a new position in shares of AstraZeneca in the fourth quarter worth about $29,000. Finally, FNY Investment Advisers LLC bought a new position in shares of AstraZeneca in the first quarter worth about $29,000. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Stock Performance

Shares of NASDAQ:AZN traded up $0.68 during midday trading on Thursday, reaching $73.68. The company's stock had a trading volume of 5,766,988 shares, compared to its average volume of 3,770,284. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. The stock has a fifty day moving average of $71.08 and a 200 day moving average of $71.07. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The firm has a market capitalization of $228.51 billion, a PE ratio of 29.59, a P/E/G ratio of 1.34 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the prior year, the firm posted $2.06 earnings per share. The company's revenue was up 7.2% compared to the same quarter last year. On average, equities analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AZN. BNP Paribas initiated coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price for the company. Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a report on Wednesday, July 9th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, AstraZeneca has an average rating of "Moderate Buy" and an average target price of $89.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.